REALBiTE: Real-world analysis of epcoritamab and glofitamab in patients with R/R LBCL

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASH 2024

Lymphoma

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Lung, Respiratory and Thoracic Cancer

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

ESMO Open

Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N

doi: 10.1016/j.esmoop.2024.103464

ASCO 2024

Genitourinary Cancer

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

Breast Cancer

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Eur J Cancer

Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L

doi: 10.1016/j.ejca.2024.115113

Further Publications

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

J Natl Cancer Inst

Zerdes I, Filis P, Fountoukidis G, El-Naggar AI, Kalofonou F, D'Alessio A, Pouptsis A, Foukakis T, Pentheroudakis G, Ahlgren J, Smith D, Valachis A

doi: 10.1093/jnci/djaf015

Lymphoma

Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma

Adv Ther

Richey M, Fullerton C, Zhang Q, Williams T, Donnelly D, Wise HC, Dolor A, Wadé N, Magee K

doi: 10.1007/s12325-025-03143-5

ASH 2024

Lymphoma

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Liso-cel is effective and safe in a broad real-world population of R/R LBCLa patients, including second-line setting and secondary CNS involvement

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Real-world analysis: Improved PSA response with apalutamide versus abiraterone acetate in patients with de novo mHSPC

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

Analysis of Real-World Progression and Insufficient Response Variables and Related Endpoints Among Patients with Non-Hodgkin Lymphoma

Improved management of CRS and ICANS in patients with R/R LBCL treated with axi-cel in clinical practice

Liso-cel is effective and safe in a broad real-world population of R/R LBCL^a patients, including second-line setting and secondary CNS involvement